Akeso, Inc. Doses First Patient in a Clinical Study of Anti-TIGIT Monoclonal Antibody (AK127) in Combination with Cadonilimab (Anti-PD-1/CTLA-4) for Treatment of Advanced or Metastatic Solid Tumors
Akeso Will Publish Six Latest Research Results at the SITC 2021
Rapid Advancement of Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma
Who We Are?
About Us

Akeso,Inc. (HKEX Code: 9926.HK) is a clinical-stage biopharmaceutical company committed to in-house discovery, development and commercialization of first-in-class and best-in-class therapies. The Company dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. Akeso’s vision is to become a global leader in developing, manufacturing and commercializing innovative, next-generation and affordable therapeutic antibodies for patients worldwide.
The Company’s business is designed to drive success through both efficient and breakthrough R&D innovation. Since its inception, the Company has had the foresight to develop an end-to-end platform, Akeso Comprehensive Exploration platform (“ACE Platform”), encompassing comprehensive drug discovery and development functionalities, including target validation, antibody drug discovery and development, CMC, and GMP-compliant manufacturing...

Foreign cooperation

If you have any products or opportunities to cooperate and develop with us

图层 0 (4) logo图层 2 (1) logo图层 1 (1) logo图层 3 (1) logo图层 4 (1) logo
Product pipeline

We have One of the richest and most diversified innovative antibody drug pipeline in China

组 6 (2) logo